---
title: Can new medication improve movement
nct_id: NCT07725562
phase: PHASE2, PHASE3
status: RECRUITING
sponsor: Zhejiang Vimgreen Pharmaceuticals, Ltd.
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT07725562"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07725562"
last_fetched: "2026-07-24T14:00:57.553Z"
source: "Parkinson's Pathways (curated)"
---
# Can new medication improve movement

**Goal (in five words):** Can new medication improve movement

**Official Title:** A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase IIb Clinical Trial to Evaluate the Efficacy and Safety of Oral VG081821AC Tablets Monotherapy (Without Concomitant Levodopa) in Patients With Early to Mid-Stage Parkinson's Disease

**Trial ID:** [NCT07725562](https://clinicaltrials.gov/study/NCT07725562)

## Key Facts

- **Phase:** PHASE2, PHASE3
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** Zhejiang Vimgreen Pharmaceuticals, Ltd.
- **Target Enrollment:** 152 participants
- **Start Date:** 2026-07-17
- **Completion Date:** 2027-10-01
- **Conditions:** Parkinson Disease (PD)
- **Interventions:** VG081821AC, Placebo
- **Intervention Types:** DRUG, OTHER

## Summary For Families

They are testing whether a new oral medication called VG081821AC can improve movement symptoms in people with early to mid-stage Parkinson's, measured by change on a standard movement exam (MDS-UPDRS Part III) after 12 weeks. VG081821AC works by blocking a brain protein called the adenosine A2A receptor, and the trial gives one of three doses twice daily or a placebo while participants do not take levodopa, so researchers can see if it helps on its own. The study will enroll 152 adults in China, ages 18 to 80, diagnosed within the last seven years with moderate symptoms (stages 1 to 3) and a movement score of at least 22, and who have not used levodopa for at least four weeks.

## What This Actually Involves

**Placebo** _(From the protocol)_: This trial has 4 groups, and 1 is a placebo group. Because assignment is random, you have about a 1 in 4 chance (roughly 25%) of being in the placebo group, assuming the groups are filled equally. Ask the coordinator to confirm the exact assignment ratio.

**Visits** _(From the protocol)_: You will visit the study center 8 times for study checks.
  > "Participants will visit the study center 8 times to have their movement symptoms, safety, and overall health checked."

**Procedures** _(Ask the coordinator)_: Ask the coordinator what tests and procedures are involved, for example blood draws, scans, or questionnaires, and whether any are uncomfortable or invasive.

**Washout** _(From the protocol)_: If you previously took levodopa-containing anti-Parkinson drugs, you must have stopped them for a 4-week washout period before screening.
  > "(Note: Patients who have previously taken levodopa-containing anti-Parkinson drugs can participate in this trial after a 4-week washout period)."

**Travel & reimbursement** _(Ask the coordinator)_: Ask the coordinator whether travel, parking, or your time is reimbursed or compensated, and what is covered.

_Fields marked “From the protocol” come from the trial's registry record or quoted protocol text. Fields marked “Ask the coordinator” are not reliably available and should be confirmed directly._

## Eligibility at a Glance

Key requirements found in this trial's official criteria, in plain language. Only what the listing states is shown; the study team makes the final call.

- **Disease stage:** Stage 1 on the Hoehn and Yahr scale
- **Levodopa:** Must be taking levodopa (criteria text: "have not taken anti-parkinson drugs containing levodopa within 4 weeks prior to screening \[see main text section 5")
- **Time since diagnosis:** Diagnosed within the last 7 years (criteria text: "diagnosed with parkinson's disease per the chinese diagnostic criteria for parkinson's disease (2016 edition), and time from initial diagnosis <= 7 years")
- **Movement score (MDS-UPDRS):** MDS-UPDRS movement score of at least 22 (criteria text: "mds-updrs part iii score >= 22 at screening")

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 80 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

(1). Male or female aged 18 ≤ Age ≤ 80 at the time of signing the informed consent. (2). Diagnosed with Parkinson's disease per the Chinese Diagnostic Criteria for Parkinson's Disease (2016 Edition), and time from initial diagnosis ≤ 7 years. (3). Modified Hoehn-Yahr scale rated as 1\~3 (inclusive) at screening. (4). MDS-UPDRS Part III score ≥ 22 at screening. (5). Have not taken anti-Parkinson drugs containing levodopa within 4 weeks prior to screening \[see main text section 5.7.1\] (Note: Patients who have previously taken levodopa-containing anti-Parkinson drugs can participate in this trial after a 4-week washout period). (6). Patients receiving amantadine and/or anticholinergic drugs prior to screening must have been on a stable treatment regimen for at least 4 weeks prior to screening, and the dose must not change during the study. (7). Women of childbearing potential must have a negative pregnancy test result at screening, and the participant must agree to use approved contraceptive measures throughout the study period. (8). Must provide written informed consent and be willing and able to comply with the trial protocol (e.g., able to understand and complete questionnaires, follow the visit schedule, and use the medication).

Exclusion Criteria:

(1). Presence of any medical condition that may interfere with full participation in the study, including but not limited to the following: current diagnosis of active epilepsy; history of hemolytic anemia, pulmonary embolism, respiratory depression, dementia, active psychiatric disease, severe depression, or malignant tumor. (2). History of congestive heart failure (New York Heart Association functional class 3 or 4) or known left ventricular ejection fraction \<30%. (3). History of angina pectoris, myocardial infarction, cerebrovascular accident, percutaneous coronary intervention, peripheral arterial bypass surgery, transient ischemic attack (TIA), or stroke within 3 months prior to screening. (4). History of arrhythmia or presence of uncontrolled arrhythmia, including but not limited to: atrial fibrillation, Wolff-Parkinson-White syndrome, congenital long QT syndrome, and ECG indicating QTc interval prolongation (defined as male (QTc) \> 450 ms, female (QTc) \> 470 ms); \[Fridericia formula: QTc=QT/(RR\^0.33), where RR represents the standard heart rate value, calculated by dividing 60 by the heart rate\]. (5). Use of dopamine receptor agonists, monoamine oxidase inhibitors, catechol-O-methyltransferase (COMT) inhibitors, adenosine A2A receptor antagonists, or drugs with dopamine receptor antagonist effects within 4 weeks prior to screening \[see main text section 5.7.1\]. (Note: For newly diagnosed patients undergoing an acute dopaminergic challenge test-i.e., taking a single dose of levodopa \[e.g., Madopar\] or dopamine agonist \[e.g., Apomorphine\]-they can be enrolled after a 3-day washout period). (6). History of drug or other allergies where the investigator considers participation in this study to be of high risk, or previous allergic reactions to adenosine A2A receptor antagonists, or suspected by the investigator to be allergic to the study drug or any of its components. (7). Plan to take drugs that are inhibitors or inducers of efflux transporters (P-gp, BCRP) during the study period. (8). Suffering from uncontrolled hypertension (treated or untreated) at screening, defined as systolic blood pressure \>160 mmHg or diastolic blood pressure \>100 mmHg. (Note: After establishing good blood pressure control within a reasonable timeframe, the investigator may permit re-measuring of blood pressure up to the baseline visit, at their discretion). (9). Presence of clinically significant hepatic impairment (defined as total bilirubin and/or direct bilirubin, alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) above the upper limit of the reference range, and deemed clinically significant by the investigator). (10). Presence of any of the following: positive Hepatitis B surface antigen; positive Hepatitis C virus antibody; positive Hepatitis E virus antibody; positive Human Immunodeficiency Virus (HIV) test; positive Treponema pallidum test. (11). Previous non-response to high-dose levodopa (excluding cases of malabsorption) or previous non-response to adequate dopaminergic therapy. (12). Presence of clinically significant renal impairment (creatinine clearance Ccr \<30mL/min), calculated at screening using the Cockcroft-Gault formula: Ccr (mL/min) = (140 - Age) × Weight (kg) / \[72 × Serum Creatinine (SCr) (mg/dL)\] (Female × 0.85) or Ccr (mL/min) = (140 - Age) × Weight (kg) / \[0.814 × Serum Creatinine (SCr) (μmol/L)\] (Female × 0.85). (13). Investigator judges the participant to be at risk for suicide, or if the participant answers "yes" to Question 4 and/or Question 5 of the Suicidal Ideation subscale, or any question on the Suicidal Behavior subscale of the Columbia-Suicide Severity Rating Scale (C-SSRS) at screening. (14). Investigator judges the participant to have severe psychiatric abnormalities (anxiety, depression), with a Hamilton Depression Rating Scale-17 (HAMD-17) score \>23, or a Hamilton Anxiety Rating Scale (HAMA) score \>21 at screening. (15). Participant has significant cognitive impairment or dementia, including the following scenarios: Illiterate participants (uneducated) with an MMSE score ≤19 at screening; Primary school participants (education ≤6 years) with an MMSE score ≤22 at screening; Middle school and above participants (education \>6 years) with an MMSE score ≤23 at screening. (16). History of surgical treatment for Parkinson's disease. (17). Use of repetitive transcranial magnetic stimulation, transcranial direct current stimulation, biofeedback therapy, acupuncture, traditional Chinese medicine, and other traditional rehabilitation methods within 4 weeks prior to screening (Note: Patients can participate in this trial after a 4-week washout period). (18). History of heavy alcohol consumption for more than 3 consecutive months within 1 year prior to screening, defined as: female participants drinking an average of \>20 g of alcohol daily (calculated as pure alcohol; 20 g is roughly equivalent to two 300 mL glasses of beer, 40 mL of spirits, or 140 mL of wine), and male participants drinking an average of \>30 g of alcohol daily (calculated as pure alcohol; 30 g is roughly equivalent to three 300 mL glasses of beer, 60 mL of spirits, or 210 mL of wine), or inability to reliably quantify alcohol consumption according to the investigator's judgment. (19). History of excessive tea and/or coffee consumption within the past 4 weeks, or anticipated excessive consumption during the clinical trial period. (Excessive tea consumption is defined as 4 or more cups a day, 1 cup = 250 mL; second or third steepings without adding new leaves still count as 1 cup total, not two or three. Excessive coffee consumption is defined as 2 or more cups a day, 1 cup = 250 mL; for participants who do not drink coffee every day, 2 cups per day is permissible for one day a week, but no more than 2 cups; and the defined consumption limit must not be exceeded throughout the entire trial). (20). Active substance abuse (including inhaled or injected drugs) within 1 year prior to screening. (21). Participated in another drug clinical trial (meaning received investigational drug treatment) within 3 months prior to randomization. (22). Any other condition where the investigator considers the participant unsuitable for this study.
```

## Locations (1)

- Xuanwu Hospital of Capital Medical University, Beijing, China _(39.9075, 116.3972)_
  - Chief Physician, (CONTACT), 86+10-83198899, pbchan90@gmail.com

## Central Contacts

- Yanfen Jin, Ms, (CONTACT), 86+57189010903, jinyanfen@vimgreenpharma.com

## Making Contact: How to Call This Study Site

### Who to ask for

Ask for the study coordinator. Some sites call this person the research coordinator. They are the right person for questions about joining a study. If you reach a front desk or a doctor's office scheduler, ask them to connect you with the research team for this study.

### What to say

It is fine to read this out loud, word for word:

> Hello, my name is ____. I am calling about a Parkinson's study at your site. The study number is NCT07725562. It is the one about "Can new medication improve movement". Could I speak with the study coordinator about taking part?

If you are calling for a family member, use their name and mention that you help with their care.

### What they will ask you

- The year of diagnosis
- Current medications and their doses
- Other health conditions
- Any procedures already done, such as deep brain stimulation (DBS)
- How far you are able to travel for study visits
- Whether a care partner can come to visits with you

### What to have ready

- A written list of current medications and doses
- Your neurologist's name and phone number
- The diagnosis date. The year is enough.
- A recent visit summary from the neurologist, if you have one

### What to ask them

- How many visits are there, and how long does each visit take?
  The listing already answers this: You will visit the study center 8 times for study checks. Ask the coordinator to confirm it still applies.
- Is travel, parking, or my time reimbursed?
- Is there a placebo group, and what is my chance of being in it?
  The listing already answers this: This trial has 4 groups, and 1 is a placebo group. Because assignment is random, you have about a 1 in 4 chance (roughly 25%) of being in the placebo group, assuming the groups are filled equally. Ask the coordinator to confirm the exact assignment ratio.
- Would I need to stop or pause any of my current medications?
  The listing already answers this: If you previously took levodopa-containing anti-Parkinson drugs, you must have stopped them for a 4-week washout period before screening. Ask the coordinator to confirm it still applies.
- What happens when the study ends? Could I stay on the treatment if it helps?

### What to expect

- Expect to wait a few days for a callback. A week is common. Calling or emailing again after that is fine and normal.
- Many callers do not end up joining. Screening out is common and is not a judgment about you or your health.
- Asking questions commits you to nothing. You can stop the process at any point.

---

*Canonical: https://parkinsonspathways.com/trial/NCT07725562*  
*HTML version: https://parkinsonspathways.com/trial/NCT07725562*  
*Source data: https://clinicaltrials.gov/study/NCT07725562*